Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

December 9, 2024

Molecular Cancer Therapeutics: KT-253, A Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small Molecule Inhibitors

Chutake, et al.
Read More
December 9, 2024

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

American Society of Hematology (ASH) 2024
cHL Liquid Tumors Solid Tumors
Read More
October 24, 2024

Predictive Markers of Response to the MDM2 Degrader KT-253

EORTC-NCI-AACR Symposium 2024
Liquid Tumors Solid Tumors
Read More
October 23, 2024

The MDM2 Degraders KTX-049 and KT-253 are Highly Active in Wild-type TP53 Merkel Cell Carcinoma

EORTC-NCI-AACR Symposium 2024
Solid Tumors
Read More
October 23, 2024

CDK2 Heterobifunctional Degraders Co-Degrade CDK2 and Cyclin E Resulting in Efficacy in CCNE1-Amplified and Overexpressed Cancers

EORTC-NCI-AACR Symposium 2024
Read More
June 26, 2024

Journal of Medicinal Chemistry: Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma

Weiss, et al.
Read More
June 14, 2024

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers

European Hematology Association (EHA) 2024
cHL CTCL Liquid Tumors Solid Tumors
Read More
June 1, 2024

Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of KT-253, a Targeted Protein Degrader of MDM2, in Patients with Relapsed/Refractory (R/R) Solid Tumors, Lymphoma, High Grade Myeloid Malignancies and Acute Lymphoblastic Leukemia (ALL)

American Society of Clinical Oncology (ASCO) 2024
Liquid Tumors Solid Tumors
Read More
April 7, 2024

E3 Pairing and Structural Mechanisms Underlying Anti-Tumor Activity of Clinical STAT3 Degrader KT-333

American Association for Cancer Research (AACR) 2024 Annual Meeting
Read More
December 10, 2023

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Hematology (ASH) Annual Meeting and Exposition 2024
CTCL LGL-L PTCL Solid Tumors
Read More